Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39293395.
- Also identified by DOI 10.1016/j.xcrm.2024.101726 and PMC identifier 11525015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al.<sup>1</sup> and Zhang et al.<sup>2</sup> in Cell Reports Medicine and Cell Reports, respectively, show the efficacy of peptide vaccines in eliciting an antibody response against PCSK9 and reducing plasma cholesterol levels.
Medical subject headings
- Proprotein Convertase 9
- Hypercholesterolemia
- Vaccines, Subunit